Parsippany Chapter Upcoming Events Join PCCI

Reniguard Life Sciences Inc.

A biotech company

Presenter: David Ren MD PhD, CSO of Reniguard

 

Monday, February 11, 2013

Embassy Suites, Chesterbrook, Pennsylvania (directions)

 

About

 

Reniguard's R&D in Early Detection

Although the past two decades have seen remarkable advances in the development of oncological therapeutics and personalized cancer treatments, early detection/diagnosis remains the most effective way of saving lives. Reniguard is developing mutation assays for the early detection and risk assessment of certain cancers. Reniguard is also developing assays for the early diagnosis of drug-resistance during treatment of chronic hepatitis B.

 

Technical Innovations

Cancer is a genetic disease caused by mutations or a combination of mutations with epigenetic modifications. These cancer-derived genetic materials, when detected from body fluids (blood, urine, etc), can provide useful information for cancer risk assessment, early diagnosis, post-surgery monitoring and prognosis purposes. However, this requires the detection methods to be ultra-sensitive and preferably quantitative. Body fluids contain normal non-mutated DNAs which suppress the detection of mutated DNAs. As the amount of mutated DNAs is very little compared with the amount of normal DNAs at the early stage, detecting mutated DNAs is like finding "a needle in a haystack" . Scientists at Reniguard have developed mutation detection technologies that have detection sensitivities as high as 0.1 - 0.001%. This level of sensitivity makes early detection possible. They also have strong expertise in other aspects of assay development that are crucial to early detection.

 

 

3 Major Issues

 

  1. To be successful, Reniguard believes it needs a strong business partner. How should Reniguard go about finding a CEO/business development partner when we don't have significant funding in hand?

  2. Reniguard believes a solid market analysis is essential to establishing a defensible company valuation which will be critical to attracting potential investors. How can we perform or obtain a detailed market analysis with limited financial resources?

  3. Reniguard Life Sciences is seeking non-dilutive funding through SBIRs, but we also need to understand how and when to attract private investment. How can we use non-dilutive financing to attract private investors? Who should we target? And what will it take to bring private funding on board?

 

Program:

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - David Ren MD PhD, CSO of Reniguard, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests

 

 

<Top of the page>

 

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

Reniguard Webcast - 02/11/13

Contact Info:

 

 

 

Our Sponsors

 

EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center

 

<Top of the page>

 

 

 

 

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc